Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.

Chamuleau MED, Burggraaff CN, Nijland M, Bakunina K, Mous R, Lugtenburg PJ, Dierickx D, van Imhoff GW, Vermaat JSP, Marijt EAF, Visser O, Mandigers C, Bilgin YM, Beeker A, Durian MF, van Rees B, Bohmer LH, Tick LW, Boersma RS, Snijders TJF, Schouten HC, Koene HR, de Jongh E, Hijmering N, Diepstra A, van den Berg A, Arens AIJ, Huijbregts J, Hoekstra O, Zijlstra JM, de Jong D, Kersten MJ.

Haematologica. 2019 Dec 19. pii: haematol.2019.238162. doi: 10.3324/haematol.2019.238162. [Epub ahead of print]

2.

Risk factors associated with the development of moderate to severe chronic graft-versus-host disease after non-myeloablative conditioning allogeneic stem cell transplantation in patients with AML or MDS.

Kok LMC, Bungener L, de Bock GH, Biswana A, van der Wal G, van Imhoff GW, Bellido M.

Hum Cell. 2020 Jan;33(1):243-251. doi: 10.1007/s13577-019-00297-7. Epub 2019 Nov 15.

3.

Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.

Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, van der Burg-de Graauw NC, Schouten HC, Bilgin YM, Kersten MJ, Koene HR, Herbers AHE, de Jong D, Hijmering N, Lam KH, Chiţu D, Brouwer RE, van Imhoff GW; Dutch HOVON group.

Br J Haematol. 2019 Nov;187(3):347-355. doi: 10.1111/bjh.16087. Epub 2019 Jul 10.

PMID:
31290569
4.

Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer.

Rigter LS, Schaapveld M, Janus CPM, Krol ADG, van der Maazen RWM, Roesink J, Zijlstra JM, van Imhoff GW, Poortmans PMP, Beijert M, Lugtenburg PJ, Visser O, Snaebjornsson P, van Eggermond AM, Aleman BMP, van Leeuwen FE, van Leerdam ME.

Cancer Med. 2019 Jan;8(1):190-199. doi: 10.1002/cam4.1922. Epub 2018 Dec 27.

5.

Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma.

Nijland M, Seitz A, Terpstra M, van Imhoff GW, Kluin PM, van Meerten T, Atayar Ç, van Kempen LC, Diepstra A, Kok K, van den Berg A.

Cancers (Basel). 2018 Nov 20;10(11). pii: E459. doi: 10.3390/cancers10110459.

6.

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.

Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, Tonino S, Hutchings M, Spiering M, Liu R, van Tinteren H, Kersten MJ.

Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31. No abstract available.

7.

ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients.

Hutchings M, Ladetto M, Buske C, de Nully Brown P, Ferreri AJM, Pfreundschuh M, Schmitz N, Balari AS, van Imhoff G, Walewski J; ESMO Lymphoma Consensus Conference Panel Members.

Ann Oncol. 2018 Aug 1;29(8):1687-1700. doi: 10.1093/annonc/mdy167.

8.

Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.

Oosten LEM, Chamuleau MED, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK, Smeekes OS, Kersten MJ, Hardi L, Baars JW, Demandt AMP, Stevens WBC, Nijland M, van Imhoff GW, Brouwer R, Uyl-de Groot CA, Kluin PM, de Jong D, Veelken H.

Ann Hematol. 2018 Feb;97(2):255-266. doi: 10.1007/s00277-017-3167-7. Epub 2017 Dec 6.

9.

Relapse in stage I(E) diffuse large B-cell lymphoma.

Nijland M, Boslooper K, van Imhoff G, Kibbelaar R, Joosten P, Storm H, van Roon EN, Diepstra A, Kluin-Nelemans HC, Hoogendoorn M.

Hematol Oncol. 2018 Apr;36(2):416-421. doi: 10.1002/hon.2487. Epub 2017 Oct 30.

10.

MYC expression and translocation analyses in low-grade and transformed follicular lymphoma.

Aukema SM, van Pel R, Nagel I, Bens S, Siebert R, Rosati S, van den Berg E, Bosga-Bouwer AG, Kibbelaar RE, Hoogendoorn M, van Imhoff GW, Kluin-Nelemans HC, Kluin PM, Nijland M.

Histopathology. 2017 Dec;71(6):960-971. doi: 10.1111/his.13316. Epub 2017 Oct 17.

PMID:
28730642
11.

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.

Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerdt O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M; European Organisation for Research and Treatment of Cancer Lymphoma Group, and; Groupe d'Étude des Lymphomes de l'Adulte.

Eur J Cancer. 2017 Aug;81:45-55. doi: 10.1016/j.ejca.2017.05.005. Epub 2017 Jun 8.

PMID:
28601705
12.

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

Nijland M, Veenstra RN, Visser L, Xu C, Kushekhar K, van Imhoff GW, Kluin PM, van den Berg A, Diepstra A.

Oncoimmunology. 2017 Mar 3;6(4):e1295202. doi: 10.1080/2162402X.2017.1295202. eCollection 2017.

13.

Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.

André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J.

J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14.

PMID:
28291393
14.

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MDC, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A.

J Clin Oncol. 2017 Feb 10;35(5):544-551. doi: 10.1200/JCO.2016.69.0198. Epub 2016 Dec 28.

PMID:
28029326
15.

Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC.

Plattel WJ, Alsada ZN, van Imhoff GW, Diepstra A, van den Berg A, Visser L.

Br J Haematol. 2016 Dec;175(5):868-875. doi: 10.1111/bjh.14317. Epub 2016 Sep 9.

PMID:
27610595
16.

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.

Doorduijn JK, van Imhoff GW, van der Holt B, Schouten HC, Schaafsma MR, MacKenzie MA, Baars JW, Kersten MJ, Lugtenburg PJ, van den Bent MJ, Enting RH, Spoelstra FM, Poortmans P, Bromberg JEC.

Hematol Oncol. 2017 Dec;35(4):497-503. doi: 10.1002/hon.2342. Epub 2016 Aug 17.

PMID:
27530779
17.

European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.

Zinzani PL, Karlin L, Radford J, Caballero D, Fields P, Chamuleau ME, d'Amore F, Haioun C, Thieblemont C, González-Barca E, García CG, Johnson PW, van Imhoff GW, Ng T, Dwyer K, Morschhauser F.

Haematologica. 2016 Oct;101(10):e407-e410. Epub 2016 Jul 14. No abstract available.

18.

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE.

N Engl J Med. 2015 Dec 24;373(26):2499-511. doi: 10.1056/NEJMoa1505949.

19.

Bone Marrow Function After (131)I Therapy in Patients With Differentiated Thyroid Carcinoma.

Prinsen HT, Klein Hesselink EN, Brouwers AH, Plukker JT, Sluiter WJ, van der Horst-Schrivers AN, van Imhoff GW, Links TP.

J Clin Endocrinol Metab. 2015 Oct;100(10):3911-7. doi: 10.1210/jc.2015-2124. Epub 2015 Aug 11.

PMID:
26262436
20.

Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).

Poiré X, Labopin M, Cornelissen JJ, Volin L, Richard Espiga C, Veelken JH, Milpied N, Cahn JY, Yacoub-Agha I, van Imhoff GW, Michallet M, Michaux L, Nagler A, Mohty M.

Am J Hematol. 2015 Aug;90(8):719-24. doi: 10.1002/ajh.24069. Erratum in: Am J Hematol. 2016 May;91(5):E301.

21.

Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells.

Te Boome LC, Mansilla C, van der Wagen LE, Lindemans CA, Petersen EJ, Spierings E, Thus KA, Westinga K, Plantinga M, Bierings M, Broers AE, Cuijpers ML, van Imhoff GW, Janssen JJ, Huisman C, Zeerleder S, Huls G, Boelens JJ, Wulffraat NM, Slaper-Cortenbach IC, Kuball J.

Leukemia. 2015 Sep;29(9):1839-46. doi: 10.1038/leu.2015.89. Epub 2015 Apr 3.

PMID:
25836589
22.

Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide.

Morris C, de Wreede L, Scholten M, Brand R, van Biezen A, Sureda A, Dickmeiss E, Trneny M, Apperley J, Chiusolo P, van Imhoff GW, Lenhoff S, Martinelli G, Hentrich M, Pabst T, Onida F, Quinn M, Kroger N, de Witte T, Ruutu T; Chronic Malignancies and Lymphoma Working Parties of EBMT.

Transfusion. 2014 Oct;54(10):2514-22. doi: 10.1111/trf.12759. Epub 2014 Jun 26.

PMID:
24964911
23.

The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing.

Liu Y, Abdul Razak FR, Terpstra M, Chan FC, Saber A, Nijland M, van Imhoff G, Visser L, Gascoyne R, Steidl C, Kluiver J, Diepstra A, Kok K, van den Berg A.

Leukemia. 2014 Nov;28(11):2248-51. doi: 10.1038/leu.2014.201. Epub 2014 Jun 20. No abstract available.

PMID:
24947018
24.

Splenectomy and second malignancies in patients with Hodgkin lymphoma.

Kooistra HA, Kluin-Nelemans HC, van Imhoff GW, van Dijk BA, de Bock GH, van der Kaaij MA.

Leuk Lymphoma. 2015 Jan;56(1):230-1. doi: 10.3109/10428194.2014.910658. Epub 2014 May 12. No abstract available.

PMID:
24707939
25.

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C.

J Clin Oncol. 2014 Apr 20;32(12):1188-94. doi: 10.1200/JCO.2013.51.9298. Epub 2014 Mar 17.

PMID:
24637998
26.

Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma.

Liang Z, Diepstra A, Xu C, van Imhoff G, Plattel W, Van Den Berg A, Visser L.

PLoS One. 2014 Jan 28;9(1):e87474. doi: 10.1371/journal.pone.0087474. eCollection 2014.

27.

The clinical course of hepatitis E virus infection in patients of a tertiary Dutch hospital over a 5-year period.

Riezebos-Brilman A, Verschuuren EA, van Son WJ, van Imhoff GW, Brügemann J, Blokzijl H, Niesters HG.

J Clin Virol. 2013 Nov;58(3):509-14. doi: 10.1016/j.jcv.2013.08.022. Epub 2013 Sep 4.

PMID:
24055152
28.

PML nuclear bodies and SATB1 are associated with HLA class I expression in EBV+ Hodgkin lymphoma.

Liu Y, van den Berg A, Veenstra R, Rutgers B, Nolte I, van Imhoff G, Visser L, Diepstra A.

PLoS One. 2013 Aug 29;8(8):e72930. doi: 10.1371/journal.pone.0072930. eCollection 2013.

29.

Hematopoietic stem cell transplantation in patients with lymphomatoid granulomatosis: a European group for blood and marrow transplantation report.

Siegloch K, Schmitz N, Wu HS, Friedrichs B, van Imhoff GW, Montoto S, Holler E, Ribera JM, Delage R, Dührsen U, Castillo N, Harrison B, Dreger P, Sureda A; Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT).

Biol Blood Marrow Transplant. 2013 Oct;19(10):1522-5. doi: 10.1016/j.bbmt.2013.07.023. Epub 2013 Aug 13. Erratum in: Biol Blood Marrow Transplant. 2014 Feb;20(2):290. Castillo, Nerea Del [corrected to Castillo, Nerea].

30.

Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia.

Vos JM, Minnema MC, Wijermans PW, Croockewit S, Chamuleau ME, Pals ST, Klein SK, Delforge M, van Imhoff GW, Kersten MJ; HOVON Multiple Myeloma Working Party; HOVON Lymphoma Working Party.

Neth J Med. 2013 Mar;71(2):54-62.

31.

Scrotal irradiation in primary testicular lymphoma: review of the literature and in silico planning comparative study.

Brouwer CL, Wiesendanger EM, van der Hulst PC, van Imhoff GW, Langendijk JA, Beijert M.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):298-308. doi: 10.1016/j.ijrobp.2012.06.019. Epub 2012 Jul 24. Review.

PMID:
22836054
32.

HLA associations in classical Hodgkin lymphoma: EBV status matters.

Huang X, Kushekhar K, Nolte I, Kooistra W, Visser L, Bouwman I, Kouprie N, Veenstra R, van Imhoff G, Olver B, Houlston RS, Poppema S, Diepstra A, Hepkema B, van den Berg A.

PLoS One. 2012;7(7):e39986. doi: 10.1371/journal.pone.0039986. Epub 2012 Jul 10.

33.

Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups.

Urayama KY, Jarrett RF, Hjalgrim H, Diepstra A, Kamatani Y, Chabrier A, Gaborieau V, Boland A, Nieters A, Becker N, Foretova L, Benavente Y, Maynadié M, Staines A, Shield L, Lake A, Montgomery D, Taylor M, Smedby KE, Amini RM, Adami HO, Glimelius B, Feenstra B, Nolte IM, Visser L, van Imhoff GW, Lightfoot T, Cocco P, Kiemeney L, Vermeulen SH, Holcatova I, Vatten L, Macfarlane GJ, Thomson P, Conway DI, Benhamou S, Agudo A, Healy CM, Overvad K, Tjønneland A, Melin B, Canzian F, Khaw KT, Travis RC, Peeters PH, González CA, Quirós JR, Sánchez MJ, Huerta JM, Ardanaz E, Dorronsoro M, Clavel-Chapelon F, Bueno-de-Mesquita HB, Riboli E, Roman E, Boffetta P, de Sanjosé S, Zelenika D, Melbye M, van den Berg A, Lathrop M, Brennan P, McKay JD.

J Natl Cancer Inst. 2012 Feb 8;104(3):240-53. doi: 10.1093/jnci/djr516. Epub 2012 Jan 27.

34.

Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma.

Xu C, Plattel W, van den Berg A, Rüther N, Huang X, Wang M, de Jong D, Vos H, van Imhoff G, Viardot A, Möller P, Poppema S, Diepstra A, Visser L.

Haematologica. 2012 Apr;97(4):572-8. doi: 10.3324/haematol.2011.056101. Epub 2011 Dec 16.

35.

Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma.

Plattel WJ, van den Berg A, Visser L, van der Graaf AM, Pruim J, Vos H, Hepkema B, Diepstra A, van Imhoff GW.

Haematologica. 2012 Mar;97(3):410-5. doi: 10.3324/haematol.2011.053199. Epub 2011 Nov 4.

36.

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.

Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, Maertens J, Attal M, Rambaldi A, Crawley C, Luan JJ, Brune M, Wittnebel S, Cook G, van Imhoff GW, Pfreundschuh M, Sureda A; Lymphoma Working Party of European Blood and Marrow Transplantation Registry (EBMT).

Biol Blood Marrow Transplant. 2012 May;18(5):788-93. doi: 10.1016/j.bbmt.2011.10.010. Epub 2011 Oct 17.

37.

Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups.

Huang X, Kushekhar K, Nolte I, Kooistra W, Visser L, Bouwman I, Kouprie N, Veenstra R, van Imhoff G, Olver B, Houlston RS, Poppema S, Diepstra A, Hepkema B, van den Berg A.

Blood. 2011 Nov 10;118(19):5211-7. doi: 10.1182/blood-2011-04-342998. Epub 2011 Sep 14. Retraction in: Blood. 2012 Apr 5;119(14):3370.

PMID:
21921049
38.

Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study.

Pollard RP, Pijpe J, Bootsma H, Spijkervet FK, Kluin PM, Roodenburg JL, Kallenberg CG, Vissink A, van Imhoff GW.

J Rheumatol. 2011 Oct;38(10):2198-208. doi: 10.3899/jrheum.110077. Epub 2011 Aug 15.

PMID:
21844152
39.

Acute painful lumbosacral paresthesia after intrathecal rituximab.

Bromberg JE, Doorduijn JK, Baars JW, van Imhoff GW, Enting R, van den Bent MJ.

J Neurol. 2012 Mar;259(3):559-61. doi: 10.1007/s00415-011-6190-y. Epub 2011 Aug 10. No abstract available.

40.

[Benign histiocytosis: Rosai-Dorfman disease].

Noordzij W, Weernink EE, van Imhoff GW, Kluin PM, de Haan LD.

Ned Tijdschr Geneeskd. 2011;155(27):A3176. Dutch.

PMID:
21771370
41.

Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials.

Rayman N, Lam KH, van der Holt B, Koss C, Veldhuizen D, Budel LM, Mulder AH, Verdonck LF, Delwel R, de Jong D, van Imhoff GW, Sonneveld P.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):23-32. doi: 10.3816/CLML.2011.n.003.

PMID:
21454187
42.

Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.

Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, van Putten WL, Luten M, Oudejans J, van Imhoff GW.

Ann Oncol. 2011 Jul;22(7):1595-600. doi: 10.1093/annonc/mdq635. Epub 2011 Jan 6.

43.

Double-hit B-cell lymphomas.

Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, Kluin PM.

Blood. 2011 Feb 24;117(8):2319-31. doi: 10.1182/blood-2010-09-297879. Epub 2010 Nov 30. Review.

PMID:
21119107
44.

Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis.

Schuurmans M, Bromberg JE, Doorduijn J, Poortmans P, Taphoorn MJ, Seute T, Enting R, van Imhoff G, van Norden Y, van den Bent MJ.

Br J Haematol. 2010 Oct;151(2):179-84. doi: 10.1111/j.1365-2141.2010.08328.x. Epub 2010 Aug 25.

PMID:
20738305
45.

Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma.

Plattel WJ, Kluin-Nelemans HC, de Bock GH, van Imhoff GW.

Bone Marrow Transplant. 2011 Jun;46(6):827-34. doi: 10.1038/bmt.2010.188. Epub 2010 Aug 23.

PMID:
20729926
46.

MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma.

Robertus JL, Kluiver J, Weggemans C, Harms G, Reijmers RM, Swart Y, Kok K, Rosati S, Schuuring E, van Imhoff G, Pals ST, Kluin P, van den Berg A.

Br J Haematol. 2010 Jun;149(6):896-9. doi: 10.1111/j.1365-2141.2010.08111.x. Epub 2010 Mar 15. No abstract available.

PMID:
20331457
47.

Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.

Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW.

Clin Lymphoma Myeloma. 2009 Aug;9(4):307-10. doi: 10.3816/CLM.2009.n.060.

48.

Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients.

Diepstra A, van Imhoff GW, Schaapveld M, Karim-Kos H, van den Berg A, Vellenga E, Poppema S.

J Clin Oncol. 2009 Aug 10;27(23):3815-21. doi: 10.1200/JCO.2008.20.5138. Epub 2009 May 26.

PMID:
19470931
49.

[Allogenic stem cell transplantation in the Netherlands].

Schattenberg AV, Schouten HC, Verdonck LF, Willemze R, van der Lelie J, Huijgens PC, van Imhoff GW, van Biezen A, Brand R, Hagenbeek A, de Witte T, Cornelissen JJ.

Ned Tijdschr Geneeskd. 2009 Feb 28;153(9):380-5. Dutch. No abstract available.

PMID:
19348093
50.

Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma.

Robertus JL, Harms G, Blokzijl T, Booman M, de Jong D, van Imhoff G, Rosati S, Schuuring E, Kluin P, van den Berg A.

Mod Pathol. 2009 Apr;22(4):547-55. doi: 10.1038/modpathol.2009.10. Epub 2009 Mar 13.

Supplemental Content

Loading ...
Support Center